Pharmacological treatment and current controversies in COPD.
Pharmacological treatment and current controversies in COPD.
复制标题
DOI：
10.12688/f1000research.19811.1
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
Matera, Maria Gabriella
中科院分区：
文献类型：
--
作者：
Cazzola, Mario;Rogliani, Paola;Matera, Maria Gabriella
在2019年全球慢性阻塞性肺疾病倡议(GOLD)的建议中，支气管扩张剂、皮质类固醇和抗生素仍然是治疗慢性阻塞性肺疾病的关键因素，这在一定程度上是因为我们目前无法发现能够决定性地影响疾病进程的新药。然而，近年来，已经产生了一些信息，如果使用正确，可以让我们改进现有疗法的使用。
Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.